Journal of Hepatology
Volume 53, Issue 4 , Pages 593-595 , October 2010

Prognosis indicator in acute liver failure: Is there a place for cell death markers?

  • Didier Samuel

      Affiliations

    • Corresponding Author InformationCorresponding author. Address: Centre Hepato-Biliaire, Hôpital Paul Brousse, 94800 Villejuif, France. Tel.: +33 (1) 45 59 34 03; fax: +33 (1) 45 59 38 57.
    • ,
  • Philippe Ichai

References 

  1. Bismuth H, Samuel D, Castaing D, Adam R, Saliba F, Johann M, et al. Orthotopic liver transplantation in fulminant and subfulminant hepatitis. The Paul Brousse experience. Ann Surg. 1995;222:109–119
  2. Brandsaeter B, Hockerstedt K, Friman S, Ericzon BG, Kirkegaard P, Isoniemi H, et al. Fulminant hepatic failure: outcome after listing for highly urgent liver transplantation-12 years experience in the nordic countries. Liver Transplant. 2002;8:1055–1062
  3. Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:947–954
  4. Ichai P, Samuel D. Etiology and prognosis of fulminant hepatitis in adults. Liver Transplant. 2008;14:S67–S79
  5. O’Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97:439–445
  6. Bernal W, Donaldson N, Wyncoll D, Wendon J. Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study. Lancet. 2002;359:558–563
  7. Bernuau J, Rueff B, Benhamou JP. Fulminant and subfulminant liver failure: definitions and causes. Semin Liver Dis. 1986;6:97–106
  8. Volkmann X, Anstaett M, Hadem J, Stiefel P, Bahr MJ, Lehner F, et al. Caspase activation is associated with spontaneous recovery from acute liver failure. Hepatology. 2008;47:1624–1633
  9. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, Ter Borg PC. A model to predict poor survival in patients undergoing intrahepatic portosystemic shunts. Hepatology. 2000;31:864–871
  10. Wiesner RH, Edwards EB, Freeman RB, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91–96
  11. Yantorno SE, Kremers WK, Ruf AE, Trentadue JJ, Podesta LG, Villamil FG. MELD is superior to King’s college and Clichy’s criteria to assess prognosis in fulminant hepatic failure. Liver Transplant. 2007;13:822–828
  12. Dhiman RK, Jain S, Maheshwari U, Bhalla A, Sharma N, Ahluwalia J, et al. Early indicators of prognosis in fulminant hepatic failure: an assessment of the model for end-stage liver disease (MELD) and King’s College Hospital criteria. Liver Transplant. 2007;13:814–821
  13. Bechmann LP, Jochum C, Kocabayoglu P, Sowa JP, Kassalik M, Gieseler RK, et al. Cytokeratin 18-based modification of the Meld score improves prediction of spontaneous survival after acute liver failure. J Hepatol. 2010;53:639–647
  14. O’Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet. 1993;342:273–275

PII: S0168-8278(10)00552-0

doi: 10.1016/j.jhep.2010.06.002

Journal of Hepatology
Volume 53, Issue 4 , Pages 593-595 , October 2010

Article Tools